A study of hematologic disorder in chronic obstructive pulmonary disease patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210504002

Enrollment

Registered

2021-05-04

Start date

2019-10-14

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

to study the relationship between hematologic disorders and COPD and to study various factors affecting hematologic disorders. chronic obstructive pulmonary disease, anemia, polycythemia, hemoglobin

Interventions

All chronic obstructive pulmonary disease patients visited to the COPD clinic, HRH Princess Maha Chakri Sirindhorn Medical Center Hospital between January 1, 2016, and December 31, 2019

Other

COPD

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All chronic obstructive pulmonary disease patients visited to the COPD clinic, HRH Princess Maha Chakri Sirindhorn Medical Center Hospital between January 1, 2016, and December 31, 2019.

Exclusion criteria

Exclusion criteria: Patients with other lung diseases besides COPD such as asthma, infectious lung diseases, autoimmune diseases, cancer, metabolic diseases, hematologic diseases (leukemia, lymphoma, myeloproliferative disorder, pure red cell aplasia, thalassemia, bone marrow disease Heart failure Ischemic heart disease and osteoporosis Patients who are treated with antibiotics and/or corticosteroids for a long time including any treatment that causes low immunity Patients who lack follow-up Patients with chronic renal disease stage 4 or 5 Patients without complete blood count results Dementia The variables used in this study were recorded including gender, age, body mass index(BMI), respiration rate, pulse rate, serum hemoglobin, hematocrit, leukocyte, eosinophil, mean corpuscular volume(MCV), MCHC, platelet, serum albumin, serum cholesterol, creatinine, glomerular filtration rate(GFR), peak expiratory flow rate(PEFR), post-bronchodilator FEV1, 6-minute walking distance, resting O2 saturation, frequency of exacerbations and frequency of admission.

Design outcomes

Primary

Measure	Time frame
hematologic disorders data will be collected at the nearest time that COPD is diagnosed. CBC	—

Secondary

Measure	Time frame
to study various factors affecting hematologic disorders. data will be collected at the nearest time that COPD is diagnosed. Complete blood count, biochemistry laboratory results, lung function test, 6-minute walking distance, frequency of exacerbations and admission were recorded	—

Countries

Thailand

Contacts

Public ContactPichaya Petborom

Faculty of Medicine, Srinakharinwirot University

pichaya@g.swu.ac.th0816152772

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026